Therefore, for ovarian cancer patients with poor prognosis and drug resistance, reducing or inhibiting RUNX1 gene expression in ovarian cancer combined with cisplatin therapy may have a significant therapeutic effect as a combination treatment strategy. This evidence concerns the gene RUNX1 and ovarian carcinoma.